Latest Hybridoma Technology Stories
NAGOYA, Japan, Jan. 26 /PRNewswire/ -- Medical & Biological Laboratories Co., Ltd. (MBL), with the collaboration of Osaka University, has successfully generated several fully human monoclonal antibodies against pandemic A (H1N1 and H3N2) type influenza virus by utilizing blood samples from volunteers who were inoculated with influenza vaccine. Professor Kazuyoshi Ikuta, Ph. D., at the Department of Virology, Research Institute for Microbial Diseases, Osaka University, has confirmed...
NEW YORK, Oct. 26 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment http://www.reportlinker.com/p0156557/Reportlinker-Adds-Monoclonal-Antibodies-Pipeline-Analysis-and-Competitive-Assessment.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire In the nearly 35 years since the first process for creating mAbs was introduced, they...
A U.S. drugmaker says its efforts to produce the first drug derived from human stem cells has failed clinical trials. Osiris Therapeutics of Columbia, Md., announced Tuesday that a pair of clinical trials for its drug Prochymal revealed that it was no more effective than a placebo in treating bone marrow transplant complications, The New York Times reported. The results dashed hopes that Prochymal could become the first drug mass-produced from human stem cells obtained from the bone marrow...
RICHMOND, BRITISH COLUMBIA--(Marketwire - Sept. 17, 2008) - BioCurex Inc. (OTCBB:BOCX) today announced that the Australian Patent Office has issued a notice of acceptance for a divisional application of our original patent filing. This is the first patent awarded to BioCurex for the development of therapeutic applications of its RECAF technology. All proprietary protection had previously only covered diagnostic applications, and this approval from the Australian Patent Office is a milestone...
ATHENS, Ga., July 15 /PRNewswire/ -- Abeome Corporation, a Georgia-based biotech company, announced today a strategic equity investment by Cato BioVentures and a collaboration with Cato Research Ltd., its global contract research and development organization. The investment and collaboration will help support continued development of Abeome's lead ovarian cancer project. Abeome's proprietary technology vastly improves the development of monoclonal antibodies and Abeome is deploying its...
